Kwas Kargluminowy (Carglumic Acid)

Carglumic Acid acts as an allosteric activator of carbamoyl‑phosphate synthetase I, the first enzyme of the mitochondrial urea cycle. It mimics N‑acetylglutamate, increasing carbamoyl‑phosphate production, which drives the conversion of toxic ammonia into urea for safe excretion.

The dosage of Kwas Kargluminowy is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, severity of hyperammonemia, and underlying metabolic condition. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for Carglumic Acid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative class includes sodium phenylbutyrate and sodium benzoate, which act as ammonia scavengers. Carglumic Acid directly activates the urea cycle, offering a more physiological approach. In patients with N‑acetylglutamate synthase deficiency, Carglumic Acid often provides superior ammonia control compared with scavenger drugs.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture and direct sunlight. Do not use if the packaging is damaged or if the product shows signs of degradation.

Kwas Kargluminowy is taken orally, usually with water. The exact administration schedule—such as with meals or on an empty stomach—should follow the prescribing clinician’s instructions to ensure optimal absorption and efficacy.

Serious adverse events, although rare, can include allergic reactions ranging from rash to anaphylaxis, metabolic acidosis, and hepatic dysfunction. Patients should be monitored for signs of these conditions, and treatment should be discontinued if severe reactions occur.

Carglumic Acid is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients. Caution is also advised for individuals with severe hepatic impairment or uncontrolled metabolic disorders where the urea cycle cannot be effectively engaged.